TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15254051

Group type: EXPERIMENTAL
Intervention: CEE + MPA continuous (10 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEE + MPA cyclical (10 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEE + MP (200 mg on days 1 to 12 per 28‐day cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CEE (0.625 mg/d)
Number of subjects: 0
Study: 11177038

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray, 200 microg once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 75
Study: 9193210

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1548520

Group type: EXPERIMENTAL
Intervention: 5-FU and MeCCNU
Number of subjects: 210

Group type: COMPARATOR
Intervention: Escalating 5-FU
Number of subjects: 210
Study: 2992562

Group type: EXPERIMENTAL
Intervention: HOE 498 (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOE 498 (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOE 498 (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31615196

Group type: EXPERIMENTAL
Intervention: VR-based physical and cognitive training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combined physical and cognitive training (CPC)
Number of subjects: 34
Study: 30174421

Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 159

Group type: COMPARATOR
Intervention: Diskus + HandiHaler
Number of subjects: 159

Group type: COMPARATOR
Intervention: Turbuhaler + HandiHaler
Number of subjects: 159
Study: 25933674

Group type: EXPERIMENTAL
Intervention: Mental Aerobics (MA) training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 47
Study: 25377592

Group type: EXPERIMENTAL
Intervention: FTMB (0.5, 1.5, 3.0, or 6.0 mg/kg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Herceptin(®) (6 mg/kg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: FTMB (Test)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: FTMB
Number of subjects: 118

Group type: COMPARATOR
Intervention: Herceptin(®)
Number of subjects: 118
Study: 22548384

Group type: EXPERIMENTAL
Intervention: QTcD > 60 ms
Number of subjects: 53

Group type: COMPARATOR
Intervention: QTcD ≤ 60 ms
Number of subjects: 53
Study: 20626050

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment protocol including bilateral use of acupoints (Fengchi (GB20), Taiyang (EX‐HN5), etc.), manual stimulation, 30 minutes per session, 20 needles per session, total duration of at least 10 weeks, treatment frequency of twice a week with one week rest between the first 10 and last 10 sessions.
Number of subjects: 0
Study: 19192475

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 742

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 742
Study: 16259861

Group type: EXPERIMENTAL
Intervention: Software system for randomised database study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised database study approach
Number of subjects: 0
Study: 12182290

Group type: EXPERIMENTAL
Intervention: Rigid connection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-rigid connection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (rigid vs non-rigid)
Number of subjects: 30
Study: 10548704

Group type: EXPERIMENTAL
Intervention: Ketamine (200 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fentanyl (0.2 mg)
Number of subjects: 41
Study: 7789345

Group type: EXPERIMENTAL
Intervention: Sedentary group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study: 1698039

Group type: COMPARATOR
Intervention: Pentamorphone 0.60 micrograms/kg, IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pentamorphone 0.24 micrograms/kg, IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pentamorphone 0.08 micrograms/kg, IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study: 378632

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 7167311

Group type: EXPERIMENTAL
Intervention: Infant walker, used for a minimum of 1 hr. per day from 4 months of age until the onset of bipedal locomotion.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no infant walker).
Number of subjects: 30
Study: 30448246

Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) injections
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TAC) injections
Number of subjects: 43
Study: 30566004

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg or maximum tolerated dose)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 26743240

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg/day, n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Liraglutide (0.3-0.9 mg/day, n = 19)
Number of subjects: 40
Study: 25108586

Group type: EXPERIMENTAL
Intervention: iv-B (intravenous oxytocin when anterior shoulder seen)
Number of subjects: 600

Group type: COMPARATOR
Intervention: iv-A (intravenous oxytocin after delivery of the fetus)
Number of subjects: 600

Group type: COMPARATOR
Intervention: im-A (intramuscular oxytocin after delivery)
Number of subjects: 600

Group type: COMPARATOR
Intervention: im-B (intramuscular oxytocin when anterior shoulder seen)
Number of subjects: 600
Study: 21833852

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Combination of ultrasonography and physical examination
Number of subjects: 456
Study: 20130093

Group type: EXPERIMENTAL
Intervention: 8400 IU vitamin D(3)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 17324825

Group type: EXPERIMENTAL
Intervention: 20 mg of epinastine hydrochloride
Number of subjects: 79

Group type: COMPARATOR
Intervention: 6 mg of chlorpheniramine maleate
Number of subjects: 79
Study: 15749044

Group type: EXPERIMENTAL
Intervention: adjuvant av-fistula
Number of subjects: 50

Group type: COMPARATOR
Intervention: control group (without av-fistula)
Number of subjects: 50
Study: 12002490

Group type: EXPERIMENTAL
Intervention: A‐V Impulse foot pump
Number of subjects: 229

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 229
Study: 10388229

Group type: EXPERIMENTAL
Intervention: Resected colonic segment showing cobblestone appearance characteristic of Crohn's disease
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Microscopic examination of resected colonic segment
Number of subjects: 92
Study: 7890211

Group type: EXPERIMENTAL
Intervention: 10 mg Isosorbide-5-mononitrate (Is-5-Mn)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 40 mg Isosorbide-5-mononitrate (Is-5-Mn)
Number of subjects: 25
Study: 2197583

Group type: EXPERIMENTAL
Intervention: Preoperative controlled infusion of 10 mg Propionibacterium avidum KP‐40
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 68
Study: 656269

Group type: EXPERIMENTAL
Intervention: Bumetanide (0.5-2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frusemide (dose not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bumetanide and Frusemide (high dosage in renal failure)
Number of subjects: 0
Study: 30580577

Group type: EXPERIMENTAL
Intervention: High survey response rates
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Pursuit of high response rates
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Costly pursuit of high response rates
Number of subjects: 12000
Study: 29158206

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with balance training
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual pulmonary rehabilitation (control)
Number of subjects: 400
Study: 25671798

Group type: EXPERIMENTAL
Intervention: Standard care plus endovascular treatment with thrombectomy devices
Number of subjects: 316

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 316
Study: 22308561

Group type: EXPERIMENTAL
Intervention: R&R2 ADHD program (group condition)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (waiting-list control)
Number of subjects: 31
Study: 21642681

Group type: EXPERIMENTAL
Intervention: Annual screening with CA‐125 for 6 years and transvaginal ultrasound for 4 years
Number of subjects: 78126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78126

Group type: EXPERIMENTAL
Intervention: Annual screening with CA‐125 and transvaginal ultrasound
Number of subjects: 78126
Study: 19178404

Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Skin tests (Group I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Skin tests (Group II)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Amoxicillin hapten
Number of subjects: 41
Study: 17420953

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15134106

Group type: EXPERIMENTAL
Intervention: Cataract surgery with foldable IOL implantation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (pre-surgery measurements)
Number of subjects: 68
Study: 11079280

Group type: COMPARATOR
Intervention: Oral ondansetron 16 mg plus dexamethasone 12 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral granisetron 1 mg plus dexamethasone 12 mg
Number of subjects: 61
Study: 9148022

Group type: EXPERIMENTAL
Intervention: Dra I RFLP polymorphism
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Msp I, Pst I, and Rsa I RFLPs
Number of subjects: 319

Group type: COMPARATOR
Intervention: Comparison of different genotypes among moderate alcohol consumers (n = 43) or chronic alcoholics (n = 243)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Allelic frequencies for each RFLP
Number of subjects: 319
Study: 8363029

Group type: EXPERIMENTAL
Intervention: Intravenous analgesia with tramadol/metamizol (max. tramadol 400 mg+metamizol 5 g in any 24 h) after major surgery and additional administration of piritramide as needed (max. 60 mg/24 h.i.v.)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 500 mg) after minor surgery
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Pain assessment using VAS, VRS, MPQ, and SFMPQ
Number of subjects: 168
Study: 3012072

Group type: EXPERIMENTAL
Intervention: Smoking a single 1-g marihuana cigarette containing 1.8% delta 9-tetrahydrocannabinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marihuana placebo cigarette smoking
Number of subjects: 0
Study: 31366458

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness as a marker
Number of subjects: 0
Study: 28173960

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 84496
Study: 25420618

Group type: EXPERIMENTAL
Intervention: Included condition
Number of subjects: 138

Group type: COMPARATOR
Intervention: Excluded condition
Number of subjects: 138
Study: 23803334

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 182
Study: 21784445

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Term-born children (comparison group)
Number of subjects: 176
Study: 19331486

Group type: EXPERIMENTAL
Intervention: Incentive group (received $5 for each of the 15 consent items they could answer correctly)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (received standard informed consent procedure)
Number of subjects: 31
Study: 17042168

Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction (OHI) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OHI and metronidazole dental gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OHI and subgingival scaling
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OHI and subgingival scaling plus metronidazole gel
Number of subjects: 10
Study: 15055564

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 10823100

Group type: EXPERIMENTAL
Intervention: 0.01 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.05 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1 microgram kg‐1 min‐1 remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8801192

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg twice daily for two weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (unsupplemented patients)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 32
Study: 1377455

Group type: EXPERIMENTAL
Intervention: Nalbuphine 1 mg/kg i.v.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms/kg i.v.
Number of subjects: 24
Study: 6502663

Group type: EXPERIMENTAL
Intervention: Seminar method on clinical teaching
Number of subjects: 46
Study: 31758610

Group type: EXPERIMENTAL
Intervention: UCC118 supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 7
Study: 30235384

Group type: EXPERIMENTAL
Intervention: Topical Epidermal Growth Factor (EGF) serum applied twice daily for eight weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo applied twice daily for eight weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical Epidermal Growth Factor (EGF) serum
Number of subjects: 15
Study: 27785516

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 150
Study: 24534613

Group type: EXPERIMENTAL
Intervention: Drawing
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-drawing (Control)
Number of subjects: 125
Study: 23135337

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 21187353

Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17911617

Group type: EXPERIMENTAL
Intervention: Vaccination with recombinant Bet v 1 derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimer recombinant Bet v 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fragments of recombinant Bet v 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant alone
Number of subjects: 0
Study: 16061314

Group type: EXPERIMENTAL
Intervention: Nerve decompression without transposition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Subcutaneous anterior transposition of the nerve
Number of subjects: 66
Study: 12198065

Group type: EXPERIMENTAL
Intervention: 1.5 mg IM phenylephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 mg IM phenylephrine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (N/C group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (H/C group)
Number of subjects: 90
Study: 9989959

Group type: EXPERIMENTAL
Intervention: Automated heparin control system (AutoHep) with initial bolus of heparin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Automated heparin control system (AutoHep) without initial bolus of heparin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (current clinical practice)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Automated blood sampling system
Number of subjects: 12
Study: 7486767

Group type: EXPERIMENTAL
Intervention: Short stay group (drains removed and discharged after 48 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long stay group (discharged when drainage was considered acceptable, mean postoperative stay 4.5 days)
Number of subjects: 100
Study: 1730312

Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional infertility treatment (induction of ovulation with gonadotropins followed by intrauterine artificial insemination or normal intercourse)
Number of subjects: 174
Study: 6712850

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 40
Study: 31008635

Group type: EXPERIMENTAL
Intervention: Preventive cognitive therapy (PCT), 8 weekly sessions
Number of subjects: 214

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 214
Study: 29421065

Group type: EXPERIMENTAL
Intervention: 8% topical capsaicin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study: 27103232

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored program (access to all modules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (access to FAQs, project information and counseling checklist only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored program
Number of subjects: 0
Study: 22936334

Group type: EXPERIMENTAL
Intervention: Aquatic training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Land training (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Aquatic and Land)
Number of subjects: 60
Study: 21679214

Group type: EXPERIMENTAL
Intervention: Otilonium bromide (40mg t.d.s. for 15 weeks)
Number of subjects: 356
Study: 20351868

Group type: COMPARATOR
Intervention: Web-only self-care education (access to a website and email access to a cardiac nurse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone-based sessions with a cardiac nurse (access to the website and four telephone sessions)
Number of subjects: 0
Study: 16404229

Group type: EXPERIMENTAL
Intervention: Aneurysmal SAH
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PNSAH
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 99
Study: 15656211

Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate, 3.75 mg, intramuscular injections every 28 days for 3 months)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Danazol (400 mg orally, 2 times per day for 3 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no postoperative treatment, underwent ovarian stimulation immediately after first menses within 3 months postoperatively)
Number of subjects: 41
Study: 11712342

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 15
Study: 9192396

Group type: EXPERIMENTAL
Intervention: Physician lifestyle modification (10 structured visits of 15-20 minutes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group behavior modification (32 sessions of 75 minutes)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (physician and group behavior modification)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weight loss in the first four weeks and daily food records completion
Number of subjects: 26
Study: 1556279

Group type: EXPERIMENTAL
Intervention: Cultural factors influencing adult attitudes
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Years of education
Number of subjects: 382
Study: 3925335

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 622

Group type: COMPARATOR
Intervention: Control of tonic-clonic seizures
Number of subjects: 622
Study: 31337170

Group type: EXPERIMENTAL
Intervention: TFESI with sedation
Number of subjects: 64

Group type: COMPARATOR
Intervention: TFESI without sedation
Number of subjects: 64
Study: 28944524

Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (n = 34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure (n = 31)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (after 24 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Real continuous positive airway pressure (after 24 weeks, compliant patients)
Number of subjects: 65
Study: 27406705

Group type: EXPERIMENTAL
Intervention: PGA sheet attached to surgical wounds
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonattached side (control)
Number of subjects: 17
Study: 25164315

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 100
Study: 23146280

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with paclitaxel (E-T-CMF)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Adjuvant treatment with epirubicin followed by CMF (E-CMF)
Number of subjects: 308
Study: 20703222

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous dose of rifampin
Number of subjects: 10

Group type: COMPARATOR
Intervention: 7.5 mg dose of warfarin alone
Number of subjects: 10
Study: 18829803

Group type: EXPERIMENTAL
Intervention: Intervention group using the American Academy of Pediatrics curriculum
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1212
Study: 15677288

Group type: EXPERIMENTAL
Intervention: Social-skills program (S.S.GRIN)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 381